Nafiseh Esmaili; Hossein Mortazavi; Sheyda Chams-Davatchi; Maryam Daneshpazhoooh; Maede Rayati Damavandi; Zeinab Aryanian; Ali Akbar Amirzargar
Volume 10, Issue 1 , March 2013, , Pages 1-9
Abstract
Background: A common Human Leukocyte Antigen (HLA) class II allele, DQβ1*03:01, seems to be associated with Bullous pemphigoid (BP) in Caucasians whereas previous studies in other ethnic groups showed other HLA class II alleles as genetic predisposing factors for BP. Objective: To investigate the ...
Read More
Background: A common Human Leukocyte Antigen (HLA) class II allele, DQβ1*03:01, seems to be associated with Bullous pemphigoid (BP) in Caucasians whereas previous studies in other ethnic groups showed other HLA class II alleles as genetic predisposing factors for BP. Objective: To investigate the association of HLA class II alleles and haplotypes with BP in Iranian population. Methods: Fifty patients with Bullous pemphigoid and 180 geographically matched, healthy individuals as control group enrolled into this study. HLA typing of class II (DR and DQ alleles) was carried out using polymerase chain reaction based on sequence-specific primers method. Results: Class II DQA1 and DQB1 typing showed a significantly higher frequency of HLA-DQA1*05:01 (45% vs. 33%, p=0.03), HLA-DQB1*03:01 (36% vs. 23.6%, p=0.02) and HLA-DQB1*04:01 (4% vs. 1.6%, p=0.04) in the BP patients compared with controls. For DRB1 allele frequencies, there were no significant disease associations. The frequency of DRB1*08:01/DQA1*05:01/DQB1*03:01 (3% vs. 0%, p=0.02) haplotype showed an increase among patients compared with controls. Conclusion: Our data suggest that Iranian patients with BP present the same genetic predisposition linked to HLA-DQB1*03:01 previously reported in Caucasians.
Ali Akbar Amirzargar; Nilufar Mohseni; Mohammad Ali Shokrgozar; Zohreh Arjang; Nahid Ahmadi; Manijeh Yousefi Behzadi; Amir Amanzadeh; Fazel Shokri
Abstract
Background: Different studies have demonstrated that a small proportion of healthy individuals receiving the hepatitis B (HB) vaccine do not produce protective levels of anti-HB antibody, a phenomenon which could be linked to certain human leukocyte an-tigen (HLA) class-II alleles or haplotypes. Objectives: ...
Read More
Background: Different studies have demonstrated that a small proportion of healthy individuals receiving the hepatitis B (HB) vaccine do not produce protective levels of anti-HB antibody, a phenomenon which could be linked to certain human leukocyte an-tigen (HLA) class-II alleles or haplotypes. Objectives: The present study was under-taken to determine the frequency of HLA class-II alleles in Iranian healthy adult re-sponders and non-responders to HB vaccine. Methods: Twelve non-responders (anti-HBs antibody<10 IU/L) and 46 responders (anti-HBs antibody>100 IU/L) were tissue typed for HLA class-II. HLA-DRB1, DQB1 and DQA1 alleles were determined using polymerase chain reaction based on sequence specific primers (PCR-SSP) technique. Accessibility to excess amount of genomic DNA was possible using Epstein-Barr virus (EBV)-transformed B-cells established from all vaccinees. Results: Our results demon-strated increased frequencies of HLA- DRB1*07, DRB1*03, DRB1*04, DQB1*0201, DQA1*0201 alleles and HLA- DRB1*07/DQB1*0201/DQA1*0201 and DRB1*04/DQB1*0302/DQA1*03011 haplotypes in the non-responder group. Com-parison between responders and non-responders revealed only a significant difference for DQB1*0201 allele (p<0.05). Conclusion: These findings confirm the association of certain HLA alleles and haplotypes with the lack of antibody response to HB vaccine in an Iranian population.
Mehrnoosh Doroudchi; Abdolrasoul Talei; Helmout Modjtahedi; Alamtaj Samsami Dehaghani; Abdol Mohammad Pezeshki; Hilary Thomas; Abbas Ghaderi
Volume 2, Issue 4 , December 2005, , Pages 191-200
Abstract
Background: A soluble form of HER-2/neu extracellular domain (sHER-2) is reported to be released in the sera of metastatic breast cancer patients. Objective: To measure the level of sHER-2 in sera of 115 breast cancer patients. Methods: Serial samples of 27 patients with metastasis, 18 non-metastatic ...
Read More
Background: A soluble form of HER-2/neu extracellular domain (sHER-2) is reported to be released in the sera of metastatic breast cancer patients. Objective: To measure the level of sHER-2 in sera of 115 breast cancer patients. Methods: Serial samples of 27 patients with metastasis, 18 non-metastatic patients, 15 patients in stage 0/I and 14 patients with accompanying benign breast disease were also included in this study. Results: No significant difference was observed between sHER- 2 level in the pre-operative sera of breast cancer patients and that of healthy individuals. Only 8 out of 27 patients whom later developed metastasis showed elevated levels of sHER-2 in their first serum sample. However, a trend of increase in the level of sHER-2 was observed in 14 (51.8%) of 27 metastatic sera before clinical diagnosis of the metastasis. A significant association between sHER-2 positive status and vascular invasion of the tumor was observed (P = 0.02). In addition, significant correlation of sHER-2 level with CEA (highest r = 0.74) and CA 15.3 (highest r = 0.74) tumor marker levels in the serial sera were observed. The mean time from sHER-2 positivity to tumor metastasis was calculated to be 98 days (range = 29-174). Conclusion: Our results indicate that a relatively high percentage of Iranian patients with breast cancer show an elevated level of sHER-2 in their sera before clinical diagnosis of the tumor metastasis. Therefore, measuring the level of this oncoprotein, not only helps physicians in monitoring the patients during HERCEPTINTM therapy, but also can be helpful in choosing more aggressive treatments at the early satges of tumor metastasis.
Mehrnoosh Doroudchi; Hamidreza Dehshiri; Alamtaj Samsami Dehaghani
Volume 1, Issue 3 , December 2004, , Pages 183-188
Abstract
Background: Respiratory Syncytical virus infection is the most common cause of bronchiolitis and viral pneumonia in infancy. Objective: To investigate the placental transfer of RSV-specific IgG in Iranian mothers. Methods: The antibodies were measured in sera of 146 mother/newborn pairs using a commercially ...
Read More
Background: Respiratory Syncytical virus infection is the most common cause of bronchiolitis and viral pneumonia in infancy. Objective: To investigate the placental transfer of RSV-specific IgG in Iranian mothers. Methods: The antibodies were measured in sera of 146 mother/newborn pairs using a commercially available indirect Enzyme Linked Immunosorbent Assay (ELISA). The studied subjects were among healthy pregnant women who attended to the Zeinabieh Hospital of Shiraz University of Medical Sciences in a one year period. Results: A highly significant correlation was observed between RSV-specific IgG in newborns and mothers (r = 0.88). However, mean RSV-specific IgG antibodies in neonates was significantly higher than that of their mothers (P = 0.019). In addition, the mean cord/maternal ratio of RSV-specific IgG was detected to be 1.27 ± 0.60. Maternal blood group, age, parity, previous abortions and neonatal gestational age had no correlation with placental transfer of RSV-specific IgG antibodies. Conclusion: Our finding demonstrates that placental transfer of RSV-specific IgG antibodies is an active process and the main factor that influences this transfer is maternal concentration of these immunoglobulins.